Dermata Therapeutics, Inc. (DRMA) Investor Relations Documents

Dermata Therapeutics, Inc. (DRMA) investor relations documents from the company's IR site: 40 press releases. Read in-app with summaries. First-party data.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-21Press releaseDermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch
2026-08-17Press releaseDermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
2026-08-11Press releaseDermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026
2026-08-05Press releaseDermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational Treatment
2026-05-13Press releaseDermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026
2026-05-13Press releasePDF
2026-04-02Press releaseDermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with it
2026-03-26Press releaseDermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025
2026-03-26Press releasePDF
2026-03-10Press releaseMar 10, 2026 • 8:30am EDT Dermata Announces Appointment of Kyra Peckaitis as Vice President, Marketing
2026-03-05Press releaseDermata Opens a New Chapter with the Release of Tome Skincare
2026-01-20Press releaseDermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office
2025-11-14Press releasePDF
2025-08-13Press releasePDF
2025-05-14Press releasePDF
2025-03-17Press releasePDF
2025-01-29Press releaseDermata to Present on BioPub on January 31, 2025
2024-11-13Press releasePDF
2024-11-13Press releaseDermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
2024-10-08Press releaseDermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024
2024-09-05Press releaseDermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9
2024-08-07Press releasePDF
2024-08-07Press releaseDermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
2024-05-15Press releasePDF
2024-05-15Press releaseDermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
2024-03-21Press releasePDF
2024-03-21Press releaseDermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results
2023-11-09Press releasePDF
2023-11-09Press releaseDermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
2023-08-10Press releasePDF
2023-08-10Press releaseDermata Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
2023-05-11Press releasePDF
2023-02-21Press releasePDF
2023-02-21Press releaseDermata Therapeutics Provides Corporate Update and Reports Full Year 2022 Financial Results
2022-11-10Press releasePDF
2022-11-10Press releaseDermata Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
2022-08-15Press releasePDF
2022-08-15Press releaseDermata Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
2022-05-16Press releasePDF
2022-05-16Press releaseDermata Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

DRMA overview · DRMA earnings · DRMA financials · DRMA KPIs · DRMA ownership · DRMA peers · DRMA filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.